Suppression of tumor formation in lymph nodes by L-selectin–mediated natural killer cell recruitment by Chen, Shihao et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 202, No. 12, December 19, 2005 1679–1689 www.jem.org/cgi/doi/10.1084/jem.20051473
 
ARTICLE
 
1679
 
Suppression of tumor formation in lymph 
nodes by L-selectin–mediated natural killer 
cell recruitment
 
Shihao Chen,
 
1
 
 Hiroto Kawashima,
 
1
 
 John B. Lowe,
 
2
 
 Lewis L. Lanier,
 
3
 
 
 
and Minoru Fukuda
 
1
 
1
 
Glycobiology Program, Cancer Research Center, The Burnham Institute for Medical Research, La Jolla, CA 92037
 
2
 
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106
 
3
 
Department of Microbiology and Immunology and the Cancer Research Institute, University of California San Francisco, 
San Francisco, CA 94143
 
Natural killer (NK) cells are known to reject certain tumors in vivo; however, the ability of 
NK cells to prevent metastasis of tumors into secondary lymphoid organs has not been 
addressed. Here, we report that in tumor-bearing hosts, NK cells are recruited to regional 
lymph nodes in wild-type mice, but not in mice deficient for L-selectin or L-selectin ligands. 
By adoptive transfer and complete Freund’s adjuvant stimulation experiments, we demonstrated 
that L-selectin on NK cells and L-selectin ligands on endothelial cells are essential for NK cell 
recruitment to lymph nodes. Furthermore, freshly isolated resident lymph node NK cells 
lysed tumors efficiently, and metastasis of B16 melanoma cells to draining lymph nodes was 
suppressed in wild-type or 
 
Rag-1
 
–deficient mice, but not when NK cells were depleted. 
Although L-selectin–deficient NK cells efficiently lysed tumor cells in vitro, NK cell–dependent 
suppression of tumor metastasis was diminished in mice deficient for L-selectin or L-selectin 
ligands because of insufficient NK cell recruitment to lymph nodes. Moreover, tumor 
metastasis was substantially inhibited in L-selectin–deficient mice reconstituted with wild-
type NK cells. These findings indicate that L-selectin–mediated NK cell recruitment plays a 
crucial role in the control of tumor metastasis into secondary lymphoid organs.
 
In adults, NK cells develop from bone marrow–
derived precursors, and the mature NK cells
emigrate to peripheral tissues, including the
spleen, liver, lung, and other organs (1). NK
cells express a variety of adhesion molecules
that may direct this migration (2). These mole-
cules include integrins LFA-1/
 
 
 
L
 
 
 
2
 
, Mac-1/
 
 
 
M
 
 
 
2
 
, very late antigen (VLA)-4/
 
 
 
4
 
 
 
1
 
, and
VLA-2/
 
 
 
2
 
 
 
1
 
. By using in vitro migration assays
and blocking monoclonal antibodies, LFA-1
and VLA-4 have been reported to mediate the
adhesion of NK cells to resting or IL-1–activated
human umbilical vein endothelial cells (3, 4).
The interaction between VLA-4 and vascular
cell adhesion molecule–1 was shown to mediate
the recruitment of NK cells to the liver and
lung, as well as infiltration into an established
subcutaneous melanoma, after activation by
poly-I:C and IL-12 (5). In addition, LFA-1
mediates strong binding of NK cells to target
cells, thereby permitting efficient target lysis, as
shown in studies using CD11a/
 
 
 
L
 
-deficient
mice (6). Recently, the interaction between
LFA-1 and intercellular adhesion molecule–1
has been shown to be sufficient to initiate NK
cell activation and cytolysis of human inter-
cellular adhesion molecule–1-transfected 
 
Dro-
sophila
 
 SC2 cells (7).
In addition to integrins, NK cells also express
L-selectin and selectin ligands that might be
involved in adhesion and migration. L-selectin
initiates the tethering and rolling of leukocytes
over endothelial cells, the first step in a cascade
toward the recruitment of leukocytes to in-
flammatory sites. The essential role of L-selectin
in naive T lymphocyte homing to secondary
lymphoid organs has been well documented
(for reviews see references 8–10). L-selectin
expression has been reported on resting human
CD56
 
bright
 
 NK cells, which efficiently bind
peripheral lymph node (PLN) high endothelial
venules in vitro, and this binding is blocked by
an anti–L-selectin mAb (11). Although it is
generally accepted that CD56
 
bright
 
 NK cells
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develop in bone marrow and traffic to lymph nodes
through the circulation, a human CD34
 
dim
 
CD45RA
 
 
 
 he-
matopoietic precursor cell has been identified within
lymph nodes that differentiates into CD56
 
bright
 
 NK cells
when stimulated in vitro by IL-2, IL-15, or by cocultured,
activated T cells (12). Both CD56
 
bright
 
 NK cells and
CD34
 
dim
 
CD45RA
 
 
 
 precursors express L-selectin along with
other adhesion molecules, suggesting that L-selectin might
mediate this trafficking. Sialyl Lewis x oligosaccharides,
prototypic ligands for E-, L-, and P-selectins, are also
present on both resting and IL-2–activated human NK cells
(13). In vitro rolling experiments using blocking antibodies
revealed that PSGL-1 expressed on human NK cells was
essential for the binding to and rolling over Chinese ham-
ster ovary cells expressing P-selectin, whereas sialyl Lewis x
oligosaccharides on NK cells mediated the rolling over
E-selectin–expressing Chinese hamster ovary transfectants
(13). In addition, human NK cells isolated from peripheral
blood were able to tether and roll on immobilized L-selec-
tin under flow conditions (14). On mouse NK cells, how-
ever, the expression of sialyl Lewis x oligosaccharides has
not been reported.
NK cells play a critical role in tumor immunosurveillance
(15–17). They express both activating and inhibitory recep-
tors, and the integration of signals derived from these two re-
ceptor types determines the outcome (i.e., to kill or not to kill
target cells) (18). Once activated, NK cells release granzymes
and perforin, thereby eliminating transformed cells. In addi-
tion, NK cells secrete IFN-
 
 
 
, which plays critical roles in an-
tiviral defense as well as in tumor surveillance (19, 20). In hu-
mans, these two functions can be ascribed to two distinct
subsets (21–24): (a) CD56
 
dim
 
 NK cells are predominantly dis-
tributed in the spleen and peripheral blood and are strongly
cytolytic, but have less cytokine production activity; and (b)
CD56
 
bright
 
 NK cells are enriched in lymph nodes and express
only low levels of perforin, but secrete abundant IFN-
 
 
 
 when
activated by IL-2 and IL-12 or by dendritic cells, as shown in
in vitro coculture experiments (22). A low frequency of NK
cells is also found in mouse lymph nodes (25), but the mecha-
nism underling NK cell trafficking to lymph nodes is not fully
understood. A recent report showed that mouse NK cells
were recruited to lymph nodes in a CXCR3- but not
CCR7-dependent manner, and that injection of an anti–
L-selectin antibody greatly reduced this recruitment (25).
Figure 1. Antigenic phenotype and function of NK cells in lymph 
nodes. (A) NK cells in mouse lymph nodes. Single cell suspensions were 
prepared from peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN), 
spleen, and peripheral blood of wild-type C57BL/6 mice. The frequency of 
CD3 NK1.1  cells as a percentage of total lymphocytes (set by an electronic 
gate based on the light scattering profile) represents the average calculated 
based on the analysis of 25 mice. (B) Secretion of IFN-  by splenic and 
lymph node NK cells. The numbers inside the dot plots, which were gated 
on CD3 NK1.1  cells, indicate the percentage of NK cells that produced 
IFN- . One representative experiment out of three is shown. (C) Cytolysis 
of YAC-1 and RMA/S tumors by lymph node ( ) and splenic ( ) NK cells. 
Lymph node and splenic NK cells were isolated from 10 C57BL/6 mice that 
received an i.p. injection of 200  g of poly-I:C 1 d earlier. One representative 
experiment out of two is shown. 
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Whether or not mouse lymph node NK cells are a phenotyp-
ically or functionally distinct subset of NK cells, as was found
for human lymph node NK cells, remains unknown.
Here, we show that a subset of NK cells selectively traf-
fics to lymph nodes in mice, and that NK cells are recruited
to regional lymph nodes by stimulation in vivo with com-
plete Freund’s adjuvant or by metastatic B16 melanoma cells.
By using L-selectin–deficient and L-selectin ligand–deficient
mice, we demonstrate that NK cell migration to lymph
nodes under both resting and activated states is facilitated by
L-selectin expressed on NK cells, as well as by L-selectin
ligands expressed on endothelial cells. Defects in this recruit-
ment results in aggressive tumor formation in lymph nodes.
 
RESULTS
Distinct NK cell subsets in mouse lymph nodes
 
Single cell suspensions of PLNs and mesenteric lymph nodes
(MLNs) from C57BL/6 mice were analyzed for the presence
of CD3
 
 
 
NK1.1
 
 
 
 lymphocytes, which are the prototypic phe-
notype of NK cells in C57BL/6 mice (Fig. 1 A). NK cells
represented an average of 0.5% of total lymphocytes in PLNs
(pool of inguinal, axillary, brachial, and cervical nodes) and in
MLNs. NK cells comprised 
 
 
 
3.8 and 8.5% of total lympho-
cytes in the spleen and the peripheral blood, respectively.
We further found that NK cells in lymph nodes are phe-
notypically distinct from those in the spleen or blood (Table
I). As in the spleen and blood, 
 
 
 
15% of the CD3
 
 
 
NK1.1
 
 
 
cells in lymph nodes expressed the Ly49A receptor. The per-
centage of NK cells that expressed NKG2A/C/E (
 
 
 
45%)
was virtually the same in lymph nodes, spleen, and blood.
Alternately, CD3
 
 
 
NK1.1
 
 
 
 cells that coexpressed Ly49C/I
were less abundant in the PLN and MLN than in the spleen
and blood. Similarly, fewer Ly49D- or Ly49H-positive NK
cells were present in the PLN and MLN compared with
those in the spleen and blood. Virtually all NK cells ex-
pressed NKG2D receptor in these four tissues, and the ma-
jority of NK cells expressed L-selectin. Using mAb KM93
(26), we detected the expression of sialyl Lewis x oligosac-
charides on 15.9 and 25.6% of CD3
 
 
 
NK1.1
 
 
 
 cells in the
PLN and MLN, respectively. Comparing the CD3
 
 
 
NK1.1
 
 
 
cells in the spleen and peripheral blood, 7 and 5.2% reacted
with the KM93 mAb, respectively.
 
IFN-
 
 
 
 secretion and cytolysis of tumors by lymph node NK cells
 
The presence of a distinct NK cell subset in lymph nodes
suggested that they might have substantial functional differ-
ences. Therefore, we tested IFN-
 
 
 
 production and cytotox-
icity of lymph node NK cells. Consistent with a recent re-
port (25), 
 
 
 
17% (16.8 
 
 
 
 5.8) of lymph node NK cells
secreted IFN-
 
 
 
 in response to LPS stimulation (Fig. 1 B).
In contrast, after LPS stimulation, 
 
 
 
70% (74.5 
 
 
 
 5.7) of
splenic NK cells were positive for intracellular IFN-
 
 
 
 stain-
ing. Moreover, we found that freshly isolated mouse lymph
node NK cells had cytolytic activity toward YAC-1 and
RMA/S tumors equivalent to splenic NK cells (Fig. 1 C).
These results indicate that splenic and lymph node–derived
NK cells have equivalent lytic activity, but splenic NK cells
produce more INF-
 
 
 
 in mice stimulated with endotoxin.
 
L-selectin mediates the recruitment of NK cells to resting 
lymph nodes
 
Because the majority of mouse NK cells express L-selectin (Ta-
ble I), a well-characterized adhesion molecule that mediates T
and B lymphocyte homing to lymph nodes, we tested if it is also
required for NK cell trafficking to lymph nodes. To compare
the migration of wild-type and L-selectin–deficient (L-selec-
tin
 
   
 
) NK cells, we labeled wild-type (C57BL/6 or 
 
Rag-1
 
   
 
)
NK cells with the vital dye (SNARF-1) carboxylic acid ac-
etate succinimidyl ester and L-selectin
 
   
 
 NK cells with the vi-
tal dye carboxyfluorescein diacetate succinimidyl ester (CFSE),
respectively, or vice versa. A mixture containing an ap-
proximately equal number of each cell type was injected into
the tail vein of a C57BL/6 mouse. After 3, 18, or 42 h, re-
cipient tissues were collected and stained with PE-labeled
anti-NK1.1 antibody. NK1.1
 
 
 
, NK1.1
 
 
 
CFSE
 
 
 
, and NK1.1
 
 
 
SNARF-1
 
 
 
 cells were readily detected by flow cytometry
(Fig. 2 A). The relative efficiency of migration to peripheral
organs was expressed as the ratio of L-selectin
 
   
 
 NK cells
over wild-type NK cells, which was further normalized by
this ratio in peripheral blood because it serves as a reservoir for
NK cells to enter different organs. At all time points tested,
L-selectin
 
   
 
 NK cells were as abundant as wild-type NK cells
in the spleen, liver, lung, and bone marrow (Fig. 2, B and C).
In contrast, very few L-selectin
 
   
 
 NK cells entered into PLNs
(ratio 
 
 
 
 0.04–0.12) or MLNs (ratio 
 
 
 
 0.18–0.35). Fluorescent
labeling apparently had no effect on NK cell migration because
similar results were also obtained when fluorescent dyes were
switched in labeling of cells (Fig. 2, B and C). The effects of flu-
orescent dyes in NK cell migration could be further ruled out
by the observation that CFSE-labeled Core2GnT-I–deficient
(27) NK cells and SNARF-1–labeled wild-type NK cells had
the same distribution in all tissues tested (unpublished data). The
 
Table I.
 
Percentage of CD3
 
 
 
NK1.1
 
 
 
 cells that also express 
Ly49A, Ly49C/I, Ly49D, Ly49H, NKG2A/C/E, NKG2D, sialyl Lewis 
x oligosaccharides, and L-selectin
 
CD3
 
 
 
NK1.1
 
 
 
MLN PLN Spleen Blood
 
%%% %
Ly49A
 
 
 
15.4 
 
 
 
 1.1 16.8 
 
 
 
 0.9 15.5 
 
 
 
 0.4 13.2 
 
 
 
 0.1
Ly49C/I
 
 
 
26.2 
 
 
 
 3.6
 
a
 
29.6 
 
 
 
 4.9
 
a
 
50.3 
 
 
 
 3.5 63.8 
 
 
 
 3.9
Ly49D
 
 
 
33.6 
 
 
 
 4.1
 
a
 
37.6 
 
 
 
 5.6
 
a
 
50.7 
 
 
 
 3.2 52.3 
 
 
 
 1.6
Ly49H
 
 
 
33.8 
 
 
 
 0.8
 
a
 
40.3 
 
 
 
 1.3
 
a
 
50.5 
 
 
 
 0.9 53.0 
 
 
 
 1.0
NKG2A/C/E
 
 
 
50.6 
 
 
 
 3.7 45.2 
 
 
 
 2.3 43.4 
 
 
 
 1.2 44.9 
 
 
 
 1.7
NKG2D
 
 
 
100 100 100 100
sialyl Lewis x
 
 
 
25.6 
 
 
 
 3.9
 
a
 
15.9 
 
  0.7a 7.0   0.4 5.2   0.9
L-selectin  72.2   4.2 81.0   3.2 87.5   1.9 92.2   1.4
Data represent the means and SD of at least 10 mice obtained from at least four 
independent experiments. The percentage of sialyl Lewis x–expressing cells among 
CD3 NK1.1  cells was determined after removing macrophages and B cells that 
adhere to nylon fibers. 
aP   0.001 relative to blood samples.TUMOR SUPPRESSION BY L-SELECTIN–MEDIATED NK CELL RECRUITMENT | Chen et al. 1682
results indicate that L-selectin on NK cells facilitates the recruit-
ment of NK cells into resting lymph nodes.
L-selectin mediates the recruitment of NK cells to activated 
regional lymph nodes
We then investigated whether L-selectin is involved in the
trafficking of NK cells into lymph nodes during immune
Figure 2. L-selectin–mediated NK cell trafficking to lymph nodes. 
(A) Wild-type and L-selectin–deficient NK cells were labeled with SNARF-1 
and CFSE, respectively, or vice versa. A mixture was injected i.v. into a wild-
type C57BL/6 mouse. After 3, 18, or 42 h, various tissues were harvested and 
single cell suspensions were stained with anti-NK1.1 mAb and subjected 
to flow cytometric analysis. Only NK1.1  (gated) lymphocytes are shown 
42 h after the transfer. The numbers in dot plots indicate the percentages 
of transferred NK cells among all NK1.1  cells. (B) Wild-type NK cells were 
labeled with CFSE and L-selectin–deficient NK cells were labeled with 
SNARF-1. The efficiency of NK cells migrating into the tissues was 
expressed by the ratio of L-selectin–deficient NK cells to wild-type NK 
cells. White bars, black bars, and diagonally striped bars represent the 
ratios of 3, 18, and 42 h after the transfer, respectively. The data shown 
represent the average   SD of two independent experiments. (C) Wild-type 
NK cells were labeled with SNARF-1 and L-selectin–deficient NK cells were 
labeled with CFSE. Black and diagonally striped bars represent the ratios of 
18 and 42 h after the transfer, respectively. The data shown represent the 
average   SD of three independent experiments. *P   0.01 and ** P   0.001 
versus the peripheral blood.
Figure 3. CFA-induced recruitment of NK cells. (A) A mixture of 
SNARF-1–labeled wild-type NK cells and CFSE-labeled L-selectin    NK 
cells was injected i.v. into wild-type C57BL/6 mice. Immediately after 
the i.v. injection, the mice received an injection of 50  l CFA into the 
right hind footpad. Recipient popliteal lymph nodes were collected and 
analyzed for the presence of the adoptively transferred NK cells at 22 
and 42 h after CFA stimulation. The efficiency of NK cells migrating 
into lymph nodes was expressed by the ratio of L-selectin    NK cells 
to wild-type NK cells. Black bars and diagonally striped bars represent 
the ratios of 22 and 42 h after the transfer, respectively. The data 
shown represent the average   SD of two independent experiments. 
PLN refers to a pool of inguinal, axillary, and cervical nodes, representing 
unstimulated nodes. (B and C) 50  l CFA was injected into the right 
hind footpads of wild-type and mutant mice and the absolute number 
of NK cells that were recruited to the right (draining) or left (control) 
popliteal lymph nodes was determined at 24 h (B) or 48 h (C) after CFA 
stimulation. (D) The number of NK cells was also determined in the 
peripheral blood (per milliliter). The data are represented as the mean 
and SD of at least five mice for each group determined in two to six 
separate experiments. *P   0.02 and ** P   0.001 versus wild-type 
draining lymph nodes.JEM VOL. 202, December 19, 2005 1683
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stimulation in which a rapid recruitment of lymphocytes oc-
curs. Immediately after i.v. injection of fluorescent-labeled
wild-type and L-selectin    NK cells as described before,
C57BL/6 mice were injected with CFA into the right hind
footpad. The right (draining) popliteal lymph nodes were col-
lected 22 or 42 h later. As a control, we also collected the left
popliteal lymph nodes. We found that significantly fewer
adoptively transferred L-selectin    NK cells were recruited
to the draining nodes compared with wild-type NK cells (Fig.
3 A). The efficiency of L-selectin    NK cell recruitment was
only  27 and 46% (P   0.001) of wild-type NK cells at 22 or
42 h after CFA stimulation, respectively. It is noteworthy that
only   0.1% of adoptively transferred wild-type NK cells
were recruited to the draining lymph node, and the great
majority remained in the spleen and the peripheral blood.
We further examined the absolute number of NK cells
that can be recruited to the draining lymph nodes in CFA-
stimulated L-selectin    mice. In wild-type animals, CFA
induced an 11-fold increase in the absolute number of
CD3 NK1.1  cells in the draining lymph node at  24 h
(Fig. 3 B) and a 41-fold increase at  48 h (Fig. 3 C).
Without stimulation, L-selectin    popliteal lymph nodes
had significantly fewer NK cells (200   60 per node),
compared with wild-type popliteal lymph nodes (1,000  
230 per node). Notably, the number of NK cells recruited
to popliteal lymph nodes 48 h after CFA stimulation was
dramatically reduced in L-selectin    mice (5,300   1,070
per node) compared with wild-type mice (42,000  
14,000 per node), although L-selectin    mice had a simi-
lar number of NK cells in the blood (203,000   94,000/
ml) compared with wild-type mice (164,000   46,000/ml)
(Fig. 3 D). These results indicate that reduced NK cell re-
cruitment to lymph nodes is not due to the low availability
of NK cells in the circulation, but rather that it is caused by
the absence of L-selectin.
L-selectin ligands mediate the recruitment of NK cells 
to activated regional lymph nodes
We next tested whether L-selectin ligands expressed on en-
dothelial cells are also involved in NK cell migration into
lymph nodes. L-selectin ligands, sialyl Lewis x, and its sulfated
derivatives are synthesized by concerted actions of fucosyl-
transferase-IV and -VII, a sulfotransferase (LSST), and  2,3-
sialyltransferase (28). In previous studies, it has been demon-
strated that mice doubly defective in fucosyltransferase-IV and
-VII (FucT-IV   /VII   ) did not express L-selectin ligands
on high endothelial venules of PLNs (29). As expected, we
found that the total number of NK cells per node was signifi-
cantly less in the mutant mice at both 24 h (P   0.001) and
48 h (P   0.02) after CFA stimulation (Fig. 3, B and C). Be-
cause FucT-IV   /VII   -deficient NK cells migrated nor-
mally to lymph nodes when adoptively transferred to a wild-
type recipient (unpublished data), our results suggest that
fucosyltransferase-IV– and -VII–generated L-selectin ligands
in lymph nodes are crucial for the recruitment of NK cells.
Figure 4. Tumor metastasis in NK cell–depleted C57BL/6 mice. 
(A) NK cells were depleted by repeated i.p. injection of anti-NK1.1 (PK136) 
ascites, and B16-F10 metastasis was monitored as described in Materials 
and methods. Splenocytes and lymph node lymphocytes from each mouse 
were stained for CD3 and NK1.1. Significantly fewer NK1.1  cells were 
detected in the anti-NK1.1–treated mice compared with the control IgG-
treated mice because of either depletion of the NK1.1  cells or coating of 
the cells with the anti-NK1.1 antibody in vivo. The result for one representative 
mouse is shown. The numbers in the dot plots represent the percentages of 
CD3 NK1.1  cells detected among all lymphocytes. (B and C) Larger tumor 
foci were detected in anti-NK1.1–treated lymph nodes (C), compared with 
control IgG-treated lymph nodes (B). B16 refers to B16-F10 melanoma-
draining popliteal lymph nodes, whereas Control refers to the other popliteal 
lymph node. 13 mice were treated with control IgG, and 15 mice were 
injected with anti-NK1.1 antibody. Only five representative mice from each 
group are shown. (D) The relative tumor burden for each group. Symbols 
represent individual mice. Bars indicate the median values.TUMOR SUPPRESSION BY L-SELECTIN–MEDIATED NK CELL RECRUITMENT | Chen et al. 1684
Compared with wild-type C57BL/6 mice, lymph nodes
are smaller in both L-selectin    and FucT-IV   /VII   
mutants; however, the overall nodal architecture is normal.
To examine whether the size of lymph nodes affects NK cell
recruitment, we challenged Rag-1    mice, which also have
very small lymph nodes due to the lack of B and T cells,
with CFA. We found that the number of NK cells in un-
stimulated popliteal lymph nodes (150   100 per node) in
Rag-1    mice was approximately sevenfold fewer than that
in unstimulated nodes in wild-type C57BL/6 mice (Fig. 3, B
and C). However, 48 h after CFA stimulation, the number
of NK cells in the Rag-1    mice was dramatically increased
to a level similar to wild-type C57BL/6 mice (Fig. 3 C), in-
dicating that NK cells could be efficiently recruited to re-
gional lymph nodes in Rag-1    mice, and that this recruitment
does not require the presence of B or T cells.
NK cells control tumor formation in lymph nodes
Because NK cells are known to eliminate certain tumors, we
examined whether NK cells could be recruited into lymph
nodes of tumor-bearing hosts. To address this question, we in-
jected 2   106 B16-F10 melanoma cells, which aggressively
form tumors in syngeneic mice (30), into the right hind foot-
pad and monitored the development of tumor foci and the
number of tumor cells and NK cells in the draining popliteal
lymph nodes 10 d later. To confirm that NK cells are indeed
involved in the control of tumor formation in lymph nodes,
we selectively depleted NK cells with anti-NK1.1 monoclonal
antibody in C57BL/6 mice and compared the growth of tu-
mors in lymph nodes. As controls, mice were injected i.p.
with mouse IgG purified from pooled normal serum. Very
few NK1.1  cells were detected in the spleens and lymph
nodes of mice treated with anti-NK1.1 antibody, whereas
control IgG treatment had no effect on the NK cell popula-
tion (Fig. 4 A). Small tumor foci were found in control IgG-
treated mice (Fig. 4 B), whereas more extensive tumors were
found in anti-NK1.1–treated lymph nodes (Fig. 4 C). The
median of relative tumor burden, assessed by the size of tumor
mass, in control IgG-treated animals was 7%, whereas it was
40% in anti-NK1.1–treated animals (Fig. 4 D). Consistently,
the number of tumor cells in the draining lymph nodes of
anti-NK1.1–treated mice was significantly higher than control
IgG-treated lymph nodes (P   0.02; unpublished data). These
results indicate a critical role of NK cells in the inhibition of
tumor metastasis. However, we presently do not know which
types of NK cells are selectively recruited by B16 tumors be-
cause the frequency of Ly49D- and Ly49H-expressing NK
cell subsets was similar between tumor-free and tumor-bearing
lymph nodes (unpublished data).
To evaluate the potential contribution of NK/T cells,
we performed similar experiments in Rag-1    mice, which
lack T, B, and NK/T cells. Aggressive tumors were formed
in anti-NK1.1–treated, but not in control IgG-treated,
lymph nodes of Rag-1    mice (Fig. 5, A and B). Anti-
NK1.1 treatment resulted in a dramatic reduction in number
of NK cells that were recruited to the B16-bearing lymph
nodes (median   100 NK cells), compared with a median of
15,600 NK cells in control IgG-treated lymph nodes (Fig. 5
C). As a consequence, the relative tumor burden was signifi-
cantly (P   0.001) higher in anti-NK1.1–treated lymph
nodes (median   76%) than in control IgG-treated lymph
nodes (median   7%) (Fig. 5 D). The results indicate that
NK cells are the major immune cells to inhibit tumor me-
tastasis under these conditions, most likely by killing B16 tumor
cells after metastasis to lymph nodes.
L-selectin–mediated NK cell recruitment suppresses tumor 
formation in lymph nodes
Having established that NK cells inhibited B16 melanoma
metastasis to lymph nodes, we evaluated the role of L-selec-
Figure 5. Tumor metastasis in NK cell-depleted Rag-1    mice. 
(A and B) See Fig. 4 for details. The development of tumor foci in control 
IgG-treated lymph nodes (A) and anti-NK1.1–treated lymph nodes (B). 
6 out of 11 anti-NK1.1–treated and 6 out of 10 control IgG-treated lymph 
nodes are shown. (C) The number of NK cells and (D) the relative tumor 
burden in the popliteal lymph nodes bearing B16 tumors. Symbols in C 
and D represent individual mice. Bars in C and D indicate the median 
values. p-values are relative to control IgG-treated mice.JEM VOL. 202, December 19, 2005 1685
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tin and L-selectin ligands in the control of tumor formation.
In the majority of wild-type mice, we found no tumors or
only small tumor foci in the lymph nodes (Fig. 6 A). Similar
results were also found in Rag-1    mice (Fig. 6 B). In con-
trast, the popliteal lymph nodes were full of tumors in the
majority of L-selectin    mice (Fig. 6 C) and in FucT-IV   /
VII    mutant mice (Fig. 6 D). The number of NK cells re-
cruited to the tumor-bearing nodes was significantly less in
L-selectin    (median   2,000) (P   0.001) and FucT-IV   /
VII    (median   4,600) (P   0.001) mutant mice com-
pared with wild-type (median   8,100) and Rag-1    (me-
dian   15,000) animals (Fig. 6 E). Alternately, the relative
tumor burden was significantly higher in L-selectin    (me-
dian   56%, P   0.001) and FucT-IV   /VII    (median  
88%, P   0.001) mutant mice compared with wild-type
(median   6%) and Rag-1    (median   3%) animals (Fig. 6
F). The difference in tumor burden between wild-type and
L-selectin    or FucT-IV   /VII    mice was statistically
significant (P   0.001).
To exclude the possibility that L-selectin    NK cells are
intrinsically deficient for tumor recognition, we performed
in vitro cytotoxicity assays to determine the lytic activity of
L-selectin    NK cells. Our result revealed no difference be-
tween wild-type versus L-selectin    NK cells against B16
melanoma in vitro (Fig. 6 G). Collectively, these results
indicate that L-selectin–mediated interactions facilitate the
mobilization of NK cells to regional lymph nodes in re-
sponse to tumor challenge, and a defect in this trafficking
leads to aggressive tumor formation in lymph nodes.
Adoptively transferred NK cells reduce tumor metastasis 
in L-selectin–deficient mice
To further demonstrate that L-selectin on NK cells is indeed
crucial for tumor suppression, we examined whether adop-
Figure 6. Tumor metastasis in L-selectin    and FucT-IV   /VII    
mice. (A–D) B16-F10 melanoma cells were inoculated s.c. into the right 
hind footpads and the development of tumor foci was examined 10 d 
later. Tumor formation was examined in 22 C57BL/6 (A), 11 Rag-1    (B), 
26 L-selectin    (C), and 14 FucT-IV   /VII    (D) mice. Representative 
results for six mice from each group are shown. (E) The number of NK cells 
in the tumor-bearing popliteal lymph nodes. Bars indicate the median 
values. (F) The relative tumor burden in the popliteal lymph nodes bearing 
B16 tumors. Bars indicate the median values. (G) In vitro cytotoxicity of 
L-selectin    ( ) and wild-type ( ) NK cells against B16-F10 tumors. One 
out of four independent experiments is shown. p-values are relative to 
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tively transferred wild-type NK cells could reduce tumor
metastasis in L-selectin–deficient mice. Consistent with the
aforementioned results, extensive tumors were found in the
lymph nodes of L-selectin–deficient mice (Fig. 7, A and C).
In contrast, tumor formation was substantially reduced when
wild-type NK cells were adoptively transferred to L-selec-
tin–deficient mice (Fig. 7, B and C). However, statistical
analysis of the medians of the relative tumor burdens was not
significant (P   0.11), most likely due to the fact that only a
small fraction (  0.1%) of intravenously introduced NK cells
were recruited to the lymph nodes.
DISCUSSION
NK cells were originally discovered because of their ability
to kill certain tumor cells in vitro without prior sensitization
(31). The involvement of NK cells in antitumor immunity
in vivo was demonstrated subsequently in several mouse tu-
mor models by using NK cell–depleting antibodies and ge-
netically modified mutant mice (17). In these models, the in-
volvement of NK cells was demonstrated by suppression of
spontaneous or chemically induced primary tumors (32–35),
or suppression of intraperitoneally or subcutaneously inocu-
lated transplantable tumors (36–39). In models of metastatic
cancer, tumors were often injected i.v. and metastases were
monitored in the liver or lung (40, 41). Here, we show that
NK cells are also responsible for the control of tumor metastasis
into lymph nodes.
This work and a previous study (25) indicated that a
small number of NK cells are constitutively present in lymph
nodes in mice. We further showed that the cell surface anti-
genic phenotype of lymph node NK cells is different from
splenic or blood NK cells. In agreement with previous re-
ports (22, 25), we found that mouse lymph node NK cells
are capable of producing IFN- . However, unlike human
lymph node NK cells that require long-term (1 wk) stimula-
tion by IL-2 to become cytolytic (21), freshly isolated mouse
lymph node NK cells (poly-I:C-stimulated for 24 h in vivo)
were as effective as splenic NK cells in cytolysis of YAC-1
and RMA/S tumors.
Lymphocyte trafficking to lymph nodes, in particular to
the PLNs, depends on L-selectin (8, 9). Lymphocyte migra-
tion into PLNs, including popliteal lymph nodes, is almost
completely abolished in fucosyltransferase-IV and -VII dou-
ble-deficient mice due to the loss of L-selectin ligands on the
PLNs (29). We showed here that L-selectin and fucosyl-
transferase-IV– and -VII–generated L-selectin ligands are
also crucial for the recruitment of NK cells to lymph nodes
at both resting and activated states. These results indicate that
NK cells are recruited to the PLNs or MLNs through the
same mechanisms responsible for the recruitment of T and B
lymphocytes. A very low number of NK cells were still
present in resting lymph nodes of L-selectin–deficient, E-,
L-, and P-selectin triple-deficient (unpublished data), or fu-
cosyltransferase-IV and -VII double-deficient mice, suggest-
ing that molecules other than selectins are also involved.
Consistent with prior reports (5, 42), we found that the mi-
gration of NK cells to the liver and lung does not require
L-selectin. More recently, P-selectin on thymic epithelial
cells was shown to interact with ligand PSGL-1 on lymphoid
progenitors, and this interaction regulated the recruitment of
T cell progenitors to the adult thymus (43). Together, these
observations suggest that different carbohydrate–protein
interactions may function in various recruitment systems.
Rapid recruitment of lymphocytes is crucial to mount an
efficient immune response. In lymph nodes undergoing an
immune response, lymphocytes accumulate dramatically pri-
marily due to the trafficking of cells from peripheral blood
(44). We found here that NK cells were also rapidly re-
cruited to lymph nodes in response to stimulation with CFA
and by the presence of metastatic tumor cells, and this re-
cruitment was facilitated by L-selectin–mediated interac-
tions. NK cells recruited to lymph nodes by treatment with
adjuvants have been shown to provide IFN-  that is in some
cases necessary for the priming of TH1 cells (25). In addi-
tion, CFA immunization augments NK cell–mediated cyto-
Figure 7. Reduced tumor formation by adoptively transferred 
wild-type NK cells in L-selectin–deficient mice. (A and B) B16-F10 
melanoma cells were inoculated s.c. into the right hind footpads, and the 
development of tumor foci was examined 10 d later. The development of 
tumor foci in L-selectin    mice (A) and in L-selectin    mice reconstituted 
with wild-type NK cells (B), and the relative tumor burden in the popliteal 
lymph nodes bearing B16 tumors (C). Four mice were tested for each group. 
Horizontal bars in C indicate the median values.JEM VOL. 202, December 19, 2005 1687
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toxicity and induces the secretion of IFN-  (45). Recently,
CFA-stimulated NK cells have been shown to prevent dia-
betes in NOD mice (46). The recruitment of NK cells to re-
gional lymph nodes by infiltrating tumors implied that they
might play a role in the control of tumor metastasis and
growth. Indeed, NK cells were recruited to the peritoneal
cavity by MHC class I–deficient tumor cells and tumors ex-
pressing NKG2D ligands, and then became activated at this
site (36, 47, 48). The requirement of NK cells in tumor
immunity has also been demonstrated in the rejection of
RMA/S (a T cell lymphoma), EL4-S3 (a  2-microglobulin–
deficient thymoma), and RM-1 (a prostate carcinoma) (38,
39). However, other immune cells, including NK/T and
CD8  T cells, also reject tumors, depending on the model
used and the tumor dose inoculated (36, 39).
In the present study, we found that a decrease in NK cell
number correlated with an increase in tumor burden in lymph
nodes of L-selectin    and FucT-IV   /VII    mice. Because
L-selectin    NK cells effectively lysed tumors in vitro, the
observed aggressive tumor formation is therefore likely attrib-
utable to defects in the recruitment of NK cells, rather than
their lytic capacity. Reduced tumor formation by adoptive
transfer of wild-type NK cells into L-selectin–deficient host
mice provides direct evidence for the role of L-selectin–medi-
ated NK cell recruitment. In our experimental model, T and
NK/T lymphocytes do not seem to significantly contribute to
the inhibition of B16 growth in lymph nodes because Rag-1   
mice suppressed tumor formation equivalently to wild-type
animals. A predominant NK cell contribution was further
demonstrated by more extensive tumor growth in NK cell–
depleted C57BL/6 and Rag-1    mice. Together, our findings
show a mechanism by which NK cells are recruited to re-
gional lymph nodes and may provide a basis for novel ap-
proaches to treat metastatic malignancies.
MATERIALS AND METHODS
Mice. Wild-type C57BL/6 mice were purchased from Harlan Sprague
Dawley, Inc. FucT-IV   /VII    mice were obtained from the Functional
Glycomics core facility at The Scripps Research Institute and were gener-
ated as described previously (29). L-selectin    and Rag-1    mice were
purchased from The Jackson Laboratory. Mice were maintained according
to National Institutes of Health (NIH) and other institutional regulations
and guidelines.
Lymphoid organ cell isolation. PLNs (cervical, brachial, axillary, and
inguinal) and MLNs were collected in RPMI 1640 medium (Irvine Scien-
tific) supplemented with 5% FCS, 10 5 M  -mercaptoethanol ( -ME,
Sigma-Aldrich), 100  g/ml streptomycin, and 100 U/ml of penicillin (In-
vitrogen), 1  sodium pyruvate, and 1  nonessential amino acids. Single
cell suspensions were prepared by mechanical dissociation of lymph nodes
and filtered through a 70- m cell strainer (BD Labware). Splenocytes and
peripheral blood were treated with 17 mM Tris-HCl buffer (pH 7.4) con-
taining 0.83% NH4Cl to lyse red blood cells. For mAb KM93 staining, sin-
gle cell suspensions were further passed through a nylon fiber (Wako) column
to remove macrophages and B cells (49).
Antibodies and flow cytometry. Single cell suspensions were first
blocked with 4  g/ml of anti-FcR mAb 2.4G2 (mouse BD Fc Block;
BD Biosciences) and stained with the following antibodies (BD Biosci-
ences): FITC-conjugated anti-CD3 (1A17) or peridin chlorophyll protein
(PerCP)–conjugated or allophycocyanin-conjugated anti-CD3  (145-
2C11), PE-conjugated anti-NK1.1 (PK136), PE-conjugated DX5 mAb,
FITC-conjugated anti-Ly49A (A1), FITC-conjugated anti-Ly49C/I
(5E6), FITC-conjugated anti-Ly49D (4E5), FITC-conjugated anti-
NKG2A/C/E (20d5), and FITC-conjugated anti–L-selectin (Mel14).
PE-conjugated anti-NKG2D (CX5) was purchased from eBioscience.
FITC-conjugated anti-Ly49H (3D10) was provided by W. Yokoyama
(Washington University, St. Louis, MO). To determine the expression of
sialyl Lewis x oligosaccharides, mAb 2.4G2-treated cells were first stained
with mAb KM93 (CalBiochem), followed by FITC-conjugated F(ab )2
fragments of goat anti–mouse IgM (Cappel and ICN Biomedicals),
PerCP-labeled anti-CD3 , and PE-labeled anti-NK1.1. Stained cells were
analyzed on a FACSort or FACScanto flow cytometer (BD Biosciences).
Data were analyzed with FlowJo software.
Detection of intracellular IFN- . Mice were injected i.p. with 200  g
of  Escherichia coli–derived LPS (Sigma-Aldrich), and spleens and lymph
nodes were harvested 24 h later. NK cells were prepared from nylon fiber
nonadherent fractions and further negatively sorted by using a mouse NK
cell isolation kit (Miltenyi Biotec) according to manufacturer’s protocols. In
brief, 10  l of a cocktail of biotin-labeled anti-CD3, -CD14, -CD19,
-CD36, and anti-IgE antibodies was added to 107 cells resuspended in 40  l
of PBS containing 0.5% BSA and 2 mM EDTA (Buffer A). After incuba-
tion for 10 min at 6–12 C, 20  l of antibiotin-conjugated magnetic beads
were added and incubated for another 15 min. Cells were washed once
with the addition of 1–2 ml of Buffer A and subjected to magnetic sorting.
NK cells were collected in the nonbound fraction, and cultured in RPMI
1640 medium containing 10% FCS and Golgi-Stop (4  l/6 ml medium)
(BD Biosciences) for 4 h. Cells were next stained for CD3 and NK1.1 and
permeabilized with Cytofix/Cytoperm reagent (BD Biosciences). Perme-
abilized cells were stained with allophycocyanin-conjugated anti–IFN- 
and analyzed by flow cytometry.
Adoptive transfer. NK cells were isolated from donor spleens as de-
scribed before and resuspended in PBS with 2% FCS at 107 cells/ml. Cells
were labeled either with 1  M CFSE or 2.5  M SNARF-1 (GE Health-
care) at 37 C for 10 min. After three washes with RPMI 1640 medium
containing 10% FCS, cells were resuspended in ice-cold, serum-free RPMI
1640 medium. A mixture containing an approximately equal number of
wild-type C57BL/6 and mutant NK cells (1–5   106) was injected i.v. (tail
vein) into wild-type C57BL/6 mice. In some cases, wild-type NK cells
were isolated from Rag-1    spleens by passage through a nylon fiber col-
umn without further purification. After 3, 18, or 42 h, peripheral blood was
collected from the posterior vena cava, and the mouse was perfused with
PBS containing 10 U/ml heparin (Sigma-Aldrich). Single cell suspensions
of MLNs, PLNs, spleen, and peripheral blood were prepared as described
before. Bone marrow cells from one femur and one tibia were flushed with
RPMI 1640 medium containing 10% FCS. The liver and lung were minced
and digested with 50 U/ml collagenase (Roche Applied Sciences) and
0.01% DNase I (Sigma-Aldrich) at 37 C for 1 h. Tissue homogenates were
forced through a 70- m filter and centrifuged at 300 g for 5 min. Cell pel-
lets were resuspended in 20 ml (for liver) or 8 ml (for lung) of 35% Percoll
(Invitrogen) in PBS containing 200 U/ml heparin and overlaid onto 67%
Percoll in PBS (50). Samples were centrifuged at 600 g for 20 min at room
temperature without braking. Mononuclear cells were collected at the in-
terface and washed three times with PBS before antibody staining. The fre-
quency of adoptively transferred NK cells (NK1.1 CFSE  or NK1.1 
SNARF-1 ) in various organs of the recipients was determined by flow
cytometry.
CFA stimulation. 50  l CFA was injected s.c. into the right hind foot-
pad. At the indicated times, single cell suspensions were prepared from the
draining popliteal lymph nodes and stained with FITC-labeled anti-CD3
and PE-labeled anti-NK1.1 mAb. Left popliteal lymph nodes were also col-TUMOR SUPPRESSION BY L-SELECTIN–MEDIATED NK CELL RECRUITMENT | Chen et al. 1688
lected as unstimulated controls. The total cell number was determined by
using a Cell Viability Kit (BD Biosciences).
In vitro cytotoxicity assay. Splenic and lymph node NK cells were iso-
lated as described before from mice that received i.p. 200  g of poly-I:C
1 d earlier. Freshly prepared NK cells were tested for their ability to lyse
YAC-1 and RMA/S tumors in a standard 6 h 51Cr-release assay as described
previously (19). The cytolysis of B16 tumors by IL-2–activated L-selectin   
NK cells, cultured in RPMI 1640 medium containing 10% FCS and 1,000
U/ml IL-2 (Roche Applied Sciences) for 5 d, was tested in a standard 4 h
51Cr-release assay.
Tumor metastasis. The mouse melanoma cell line B16-F10 was pur-
chased from American Type Culture Collection and cultured in DME
high glucose medium (Irvine Scientific) supplemented with 10% FCS.
B16-F10 cells were harvested in cell dissociation buffer (Specialty Media),
washed three times with PBS, and resuspended in serum-free DME high
glucose medium. 2   106 B16-F10 cells were inoculated s.c. into the
right hind footpad. Right (tumor-draining) and left (control) popliteal
lymph nodes were collected 10 d later. NK cells were identified as
CD3 NK1.1  lymphocytes. Lymph node metastases are melanotic, and
occur preferentially in marginal sinuses and spread superficially to subcor-
tical regions (51). Lymph nodes were photographed. The relative tumor
burden was expressed as the percentage of tumor areas over the greatest
cross-sectional area of the lymph nodes. Area was measured by using NIH
ImageJ software.
To deplete NK cells, C57BL/6 or Rag-1    mice were injected i.p.
with 500  g of mouse control IgG (Sigma-Aldrich) or anti-NK1.1
(PK136) ascites made from nude mice (equivalent to 500  g of mouse
IgG2a) 2 d (day  2) before inoculation of B16-F10 tumors. On day 0,
B16-F10 tumors (2   106) were inoculated s.c. at footpads. Meanwhile,
mice were also given an i.p. injection of control IgG or anti-NK1.1 as-
cites. The antibody administration was repeated on days 3, 6, and 9. Mice
were killed on day 10. Popliteal lymph nodes were removed to determine
tumor formation and NK cell recruitment. It has been shown that anti-
NK1.1 antibody (PK136) treatment effectively depletes NK cells (52, 53).
In prior experiments, we confirmed the effectiveness of the NK cell de-
pletion by flow cytometry, as indicated by the absence of  2 1 integrin-
reacting DX5 mAb positively staining cells in the peripheral blood of anti-
NK1.1 mAb-treated mice (54).
To suppress tumor formation in L-selectin–deficient mice, NK cells
were isolated from 48 wild-type C57BL/6 mice as describe before, and
purified NK cells (6–10   106 cells per mouse) were injected i.v. into 4
L-selectin–deficient mice 1 day (day 1) after B16 tumors were inoculated.
Similar number of NK cells was adoptively transferred to the same mice on
days 4 and 7, and the popliteal lymph nodes were monitored for tumor for-
mation on day 10.
Statistical analysis. Significant values were determined by using the Mi-
crosoft Excel Student’s t test program or Prism Mann Whitney test. P   0.05
was considered statistically significant.
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